Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-01-26 Legal Proceedings Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces that the patents asserted against DARZALEX® in the United States have been declared invalid by summary judgment.
Legal Proceedings Report Classification · 95% confidence The document is a company announcement regarding the outcome of a patent infringement lawsuit (legal proceedings). It details a court decision declaring patents invalid. This fits the definition of a Legal Proceedings Report (LTR) as it provides an update on significant legal matters involving the company.
2019-01-26 English
Genmab Announces that the patents asserted against DARZALEX® in the United States have been declared invalid by summary judgment.
Legal Proceedings Report Classification · 95% confidence The document is a company announcement regarding a legal outcome (summary judgment on patent invalidity). It details a specific legal proceeding involving the company's product, DARZALEX. While it mentions an attachment, the text itself provides the core information about the legal development, making it a report on legal proceedings rather than just a notification of a report's publication. Therefore, it fits the 'Legal Proceedings Report' category.
2019-01-26 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is titled "Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion..." and is explicitly labeled as a "Company Announcement." It details the submission of regulatory documentation (a supplemental Biologics License Application or sBLA) to the U.S. FDA regarding a drug (daratumumab). This type of announcement, which communicates a specific regulatory action or filing event rather than providing comprehensive periodic financial results (like 10-K or IR) or being a transcript (CT), fits best under the general category of regulatory communication. Since there is no specific code for 'Regulatory Submission Announcement,' and it is not a standard financial report, it falls under the general regulatory/miscellaneous filing category, RNS, or potentially LTR if it were about legal proceedings, but here it is about a regulatory submission for approval. Given the options, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate classification for a specific, non-periodic regulatory action announcement that isn't a core financial report or a director dealing notice. The document length is substantial (15k chars), so it is not a simple RPA, but a detailed announcement of a regulatory event.
2019-01-22 English
Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion of Daratumumab in Combination with Lenalidomide and Dexamethasone in Front Line Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a formal 'Company Announcement' from Genmab regarding the initiation of a regulatory submission to the U.S. FDA. It details the clinical context (MAIA study), the nature of the submission (label expansion for Daratumumab), and provides background information on the drug and the company. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple report publication announcement (RPA) as it provides substantive news content. Therefore, it is classified as a general regulatory announcement.
2019-01-22 English
Earnings Release 2018
Earnings Release Classification · 99% confidence The document is titled "Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)" and provides specific financial figures (net sales) for a product for a past fiscal year (2018). This is a concise announcement of key financial results, not a comprehensive report (like a 10-K or IR). It fits the definition of an Earnings Release (ER), which covers initial announcements of periodical financial results (key highlights only). The length (under 5,000 characters) also suggests it is an announcement rather than the full report. FY 2018
2019-01-22 English
Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)
Earnings Release Classification · 95% confidence The document is a short company announcement (under 5,000 characters) regarding the 2018 net sales figures for a specific product (DARZALEX). It explicitly functions as a press release/announcement of financial data rather than the full financial report itself. It includes a link to an attachment, which aligns with the 'Report Publication Announcement' (RPA) category as defined by the 'Menu vs Meal' rule. FY 2018
2019-01-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.